home / stock / mrtx / mrtx quote
Last: | $58.70 |
---|---|
Change Percent: | -0.27% |
Open: | $58.86 |
Close: | $58.70 |
High: | $58.99 |
Low: | $58.54 |
Volume: | 20,994,430 |
Last Trade Date Time: | 01/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$58.7 | $58.86 | $58.7 | $58.99 | $58.54 | 20,994,430 | 01-22-2024 |
$58.8 | $58.76 | $58.8 | $59.15 | $58.64 | 2,065,753 | 01-19-2024 |
$58.82 | $58.91 | $58.82 | $58.92 | $58.8 | 321,193 | 01-18-2024 |
$58.87 | $58.91 | $58.87 | $59.25 | $58.745 | 549,416 | 01-17-2024 |
$58.98 | $59.02 | $58.98 | $59.27 | $58.97 | 4,664,691 | 01-16-2024 |
$59.28 | $58.94 | $59.28 | $59.46 | $58.85 | 660,171 | 01-15-2024 |
$59.28 | $58.94 | $59.28 | $59.46 | $58.85 | 660,171 | 01-12-2024 |
$58.89 | $58.88 | $58.89 | $59.04 | $58.84 | 612,664 | 01-11-2024 |
$58.9 | $59.01 | $58.9 | $59.11 | $58.82 | 749,015 | 01-10-2024 |
$59.04 | $59.01 | $59.04 | $59.2 | $58.84 | 2,775,896 | 01-09-2024 |
$59.09 | $58.92 | $59.09 | $59.4 | $58.895 | 844,152 | 01-08-2024 |
$59.1 | $58.84 | $59.1 | $59.35 | $58.75 | 1,307,994 | 01-05-2024 |
$58.92 | $58.81 | $58.92 | $59.22 | $58.81 | 448,795 | 01-04-2024 |
$58.9 | $59.06 | $58.9 | $59.07 | $58.9 | 362,404 | 01-03-2024 |
$59.105 | $58.75 | $59.105 | $59.175 | $58.75 | 2,268,239 | 01-02-2024 |
$58.75 | $58.94 | $58.75 | $58.94 | $58.7 | 1,834,559 | 01-01-2024 |
$58.75 | $58.94 | $58.75 | $58.94 | $58.7 | 1,834,559 | 12-29-2023 |
$58.91 | $58.9 | $58.91 | $58.98 | $58.6 | 1,706,940 | 12-28-2023 |
$58.9 | $59 | $58.9 | $59.1 | $58.88 | 2,202,167 | 12-27-2023 |
$59 | $59 | $59 | $59.2 | $58.88 | 1,373,496 | 12-26-2023 |
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...